CN Patent

CN101365806A — 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途

Assigned to Alaretti Therapeutics Europe Pte Ltd · Expires 2009-02-11 · 17y expired

What this patent protects

本发明描述了用于预测患者对化合物或医学治疗的敏感性的方法和装置。本发明还描述了在于用于鉴定表达与患者群体或亚群内的治疗敏感性或抗性相关的基因生物标记的方法。

USPTO Abstract

本发明描述了用于预测患者对化合物或医学治疗的敏感性的方法和装置。本发明还描述了在于用于鉴定表达与患者群体或亚群内的治疗敏感性或抗性相关的基因生物标记的方法。

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN101365806A
Jurisdiction: CN
Classification: —
Expires: 2009-02-11
Drug substance claim: No
Drug product claim: No
Assignee: Alaretti Therapeutics Europe Pte Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.